Be the first to like this
Complete report is available @ http://www.reportsnreports.com/reports/291517-pharmapoint-prophylactic-human-papillomavirus-vaccines-us-drug-forecast-and-market-analysis-to-2022.html .
In the US the total number of HPV vaccine doses delivered annually is likely to grow steadily over the next few years, as more males receive vaccination and Merck's nine-valent vaccine V503 becomes available in 2015. US market growth will contribute to global growth in the HPV vaccines sector. There is no indication that coverage rates for adolescent girls will increase dramatically over the forecast period, as they have been relatively stable over the past few years. However, a modest increase will likely be achieved following the introduction of V503, which will be accompanied by a marketing and awareness campaign.